Droxidopa capsules + Placebo capsules

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Symptomatic Neurogenic Orthostatic Hypotension

Conditions

Symptomatic Neurogenic Orthostatic Hypotension

Trial Timeline

Feb 11, 2016 → Sep 9, 2022

NCT ID

NCT02586623

About Droxidopa capsules + Placebo capsules

Droxidopa capsules + Placebo capsules is a approved stage product being developed by Lundbeck for Symptomatic Neurogenic Orthostatic Hypotension. The current trial status is completed. This product is registered under clinical trial identifier NCT02586623. Target conditions include Symptomatic Neurogenic Orthostatic Hypotension.

What happened to similar drugs?

2 of 16 similar drugs in Symptomatic Neurogenic Orthostatic Hypotension were approved

Approved (2) Terminated (4) Active (10)

✅valsartanNovartisApproved

✅MavacamtenBristol Myers SquibbApproved

❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3

🔄ISV-305Sun PharmaceuticalPhase 3

🔄rabeprazole sodium + PlaceboEisaiPhase 3

🔄Esomeprazole + Matching placeboAstraZenecaPhase 3

🔄Pasireotide + OctreotideNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02586623	Approved	Completed	Feb 11, 2016	Sep 9, 2022	Symptomatic Neurogenic Orthostatic Hypotension

Competing Products

20 competing products in Symptomatic Neurogenic Orthostatic Hypotension

See all competitors

Product	Company	Stage	Hype Score
Sodium hyaluronate + placebo injection	Daiichi Sankyo	Phase 3	32
ISV-305	Sun Pharmaceutical	Phase 3	40
rabeprazole sodium + Placebo	Eisai	Phase 3	40
Verinurad + Febuxostat + Dapagliflozin	AstraZeneca	Phase 2	35
RDEA3170 + Febuxostat + Benzbromarone	AstraZeneca	Phase 1/2	32
Esomeprazole + Matching placebo	AstraZeneca	Phase 3	40
DFV890 + Placebo	Novartis	Phase 2	35
Omalizumab + Omalizumab + Placebo	Novartis	Phase 2	35
Pasireotide + Octreotide	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 2	35
valsartan	Novartis	Approved	43
Atorvastatin - Cholestyramine - Sitosterol	Pfizer	Pre-clinical	26
Epoetin biosimilar	Pfizer	Pre-clinical	26
Apixaban + Standard of care	Pfizer	Phase 3	40
Azithromycin plus chloroquine	Pfizer	Phase 3	32
Mavacamten	Bristol Myers Squibb	Approved	50
Aficamten + Placebo	Sanofi	Phase 3	44
Vandetanib 300 mg	Sanofi	Pre-clinical	26
REGN7508 + Acetylsalicylic Acid (ASA) + Placebo	Regeneron Pharmaceuticals	Phase 3	47
Rivaroxaban + Placebo	Bayer	Phase 3	37